Increased phosphorylation of both AKT and ERKs was commonly observed in cancer cells treated with RAS/MAPK pathway inhibitors, suggesting the importance of the PI3K/AKT pathway in reactivating ERKs and reducing the cytostatic effect of the inhibitors (Figure 2) [61,62,118]. The gene discussed is AKT1; the disease is cancer.